The certainty of uncertainty in health technology assessment

26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...

Read more →

UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile

19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...

Read more →

Radical or not, NICE makes evidence based recommendations

19 November 2021 - Godlee’s call for the National Institute for Health and Care Excellence to keep close to its radical ...

Read more →

Bringing a consumer perspective to clinical advice

19 October 2021 - PHARMAC is making changes to the way its advisory committees work to strengthen the input of ...

Read more →

Outdated criteria for drug plan reimbursement obstruct evidence based care

12 October 2021 - An important flaw in the funding approach used by Canada’s public drug plans is highlighted by the ...

Read more →

Aetion and NICE announce collaboration to explore use of real world evidence for comparative effectiveness studies to inform clinical guidance

6 October 2021 - Collaboration will leverage the Aetion Evidence Platform to study when and how real world evidence can support ...

Read more →

U.S. Food and Drug Administration reasoning in approval decisions when efficacy evidence is borderline (2013–2018)

21 September 2021 - The U.S. FDA has substantial flexibility in its approval criteria in the context of life-threatening disease and ...

Read more →

Manufacturers’ perceptions of the decision-making process for new drug reimbursement in South Korea

17 September 2021 - This study aimed to evaluate manufacturers’ perceptions of the decision-making process for new drug reimbursement and to ...

Read more →

Consumers to have more say on medicine access issues

7 September 2021 - Consumer involvement in Australia’s medicines choices has been further strengthened under a new strategic agreement Medicines ...

Read more →

Real world outcomes associated with new cancer medicines approved by the FDA and EMA: a retrospective cohort study

August 2021 - Real world data studies are increasingly used to support regulatory approvals, reimbursement decisions, and changes in clinical practice ...

Read more →

Information Act shows racism in PHARMAC’s decision-making

17 August 2021 - Paati Māori Co-leader, Debbie Ngarewa-Packer, has received information that blatantly outlines the inequity within PHARMAC and ...

Read more →

PHARMAC must explain funding decisions

16 August 2021 - “A report this morning that all PHARMAC staff, rather than clinical experts or those with patient ...

Read more →

PHARMAC invites entire staff to top secret drug ranking meetings

16 August 2021 - Highly confidential meetings where PHARMAC ranks the funding priority of potentially life-saving medicines are open to ...

Read more →

From Our Perspective: FDA approval demonstrates the role of real world evidence in regulatory decision-making on drug effectiveness

4 August 2021 - In this CDER From Our Perspective, experts discuss the recent FDA approval of Prograf (tacrolimus) in combination ...

Read more →

Cancer patients, advocates 'gobsmacked' PHARMAC declining funding application for life-changing drug

29 July 2021 - Ovarian cancer patients and advocates are "utterly gobsmacked" Pharmac has proposed to decline a funding application ...

Read more →